Podcastblaster Podcast Directory  Podcast Directory

Podcast Search   
Podcast title GRACEcast ALL Subjects audio and video
Website URL http://cancerGRACE.org/
Description Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Updated Tue, 11 Jun 2019 15:34:31 +0000
Image GRACEcast
Category Science & Medicine
Education
Health
Subscribe

Vote for this podcast
    Currently 0.00/5

Rating: 0.0/5 (0 votes cast)

Link to this podcast GRACEcast ALL Subjects audio and video

Episodes

1. FCR vs. BR - Is One Better?
http://feedproxy.google.com/~r... download (video/x-mp4, 260.50Mb)

Description:

Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising.



2. Basics of Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 566.17Mb)

Description: Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

3. Adjuvant Chemotherapy for Elderly and Frail Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 751.20Mb)

Description: Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

4. Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 629.09Mb)

Description: Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

5. New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis
http://feedproxy.google.com/~r... download (video/x-mp4, 506.01Mb)

Description:

GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss new trials of targeting therapies used to treat leptomeningeal carcinomatosis.



6. ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments
http://feedproxy.google.com/~r... download (video/x-mp4, 344.00Mb)

Description:

GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss promising early results for treatments targeting new mutations.



7. Immuno-oncology Developments - Combinations and Use as First-Line Therapy
http://feedproxy.google.com/~r... download (video/x-mp4, 489.85Mb)

Description:

GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss Immuno-oncology developments - combinations and use as first-Line therapy.



8. Does Current Evidence Support Favoring Proton-Beam Radiation
http://feedproxy.google.com/~r... download (video/x-mp4, 588.40Mb)

Description:

GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.  

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation.



9. J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
http://feedproxy.google.com/~r... download (video/x-mp4, 740.36Mb)

Description:

GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.



10. Are There Less Toxic Alternatives to the Extreme Regimen
http://feedproxy.google.com/~r... download (video/x-mp4, 282.34Mb)

Description:

GRACE is happy to present the 9th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the topic of whether there are less toxic alternatives to the extreme regimen.



11. Promising Early Data for Oral Inhibitor Buparlisib
http://feedproxy.google.com/~r... download (video/x-mp4, 130.91Mb)

Description:

GRACE is happy to present the 8th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the promising early data for the oral inhibitor Buparlisib.



12. Using Immunotherapy as First-Line Treatment and in Combinations
http://feedproxy.google.com/~r... download (video/x-mp4, 321.24Mb)

Description:

7th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding ASCO 2016 HN RT-Using Immunotherapy as First-Line Treatment and in Combinations.



13. Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 289.86Mb)

Description:

6th video in our series ASCO 2016 Head and Neck Roundtable, featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD. Dr. Weiss moderates the discussion regarding keynote 55: Pembrolizumab for heavily pre-treated patients.  



14. Using Biomarkers in Immunotherapy
http://feedproxy.google.com/~r... download (video/x-mp4, 138.46Mb)

Description:

 

GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Bauml and Seiwert discuss the using biomarkers in immunotherapy.

 

 



15. Common Side Effects of PD-1 Inhibitors
http://feedproxy.google.com/~r... download (video/x-mp4, 295.39Mb)

Description:

GRACE is happy to present the 4th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the common side effects of PD-1 inhibitors.



16. Data from Keynote 12 Nivolumab and Pembrolizumab
http://feedproxy.google.com/~r... download (video/x-mp4, 287.55Mb)

Description:

GRACE is happy to present the 3rd video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the data presented from Keynote 12 - Nivolumab and Pembrolizumab. 



17. How Promising Are The Results From Checkmate 141?
http://feedproxy.google.com/~r... download (video/x-mp4, 208.01Mb)

Description:

GRACE is happy to present the 2nd video in our series, ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

    Drs. Weiss, Baumi and Seiwert discuss the subject of Checkmate 141 and its results.



18. Local Consolidation Therapies for Oligomatastases
http://feedproxy.google.com/~r... download (video/x-mp4, 998.19Mb)

Description:

GRACE is happy to present the 4th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of local consolidation therapies for oligomatastases.



19. The Immune System and PD-1 Inhibitors
http://feedproxy.google.com/~r... download (video/x-mp4, 117.19Mb)

Description:

GRACE is happy to present the 1st video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer.  Featuring Jared Weiss, MD, Joshua Baumi, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016.

Drs. Weiss, Baumi and Seiwert discuss the subject of the immune system and PD-1 inhibitors. 



20. Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations
http://feedproxy.google.com/~r... download (video/x-mp4, 580.09Mb)

Description:

GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of urine or blood testing instead of lung biopsy, showing promise for finding EGFR mutations. 

 

 



21. Can Online Patient Groups Speed New Targeted Therapies?
http://feedproxy.google.com/~r... download (video/x-mp4, 375.00Mb)

Description:

GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer.  Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing topics presented at ASCO 2016.

Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the subject of online patient groups and if they can help speed the development of new targeted therapies.  A subject quite important to online groups such as our own GRACE.



22. Rova-T Shows Promise in Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 395.62Mb)

Description:

1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. 

Dr. West moderates this roundtable discussion highlighting studies presented at ASCO 2016.  For this video, Rova-T is presented as showing promise in Small Cell Lung Cancer. 



23. Significance Of IGHV Mutations & How They Are Assessed
http://feedproxy.google.com/~r... download (video/x-mp4, 167.58Mb)

Description:

CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed.  Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer Institute.



24. Not Your Father's CLL
http://feedproxy.google.com/~r... download (video/x-mp4, 0.00Mb)

Description:

Faculty member Dr. John Pagel, and an in-person audience of patients and caregivers joined GRACE for 'Not Your Father's CLL', webcast LIVE from Seattle, WA on April 22, 2016.

Dr. Pagel, Chief of the Hematologic Malignancies program for the expanded treatment and research of blood based cancers such as leukemia, multiple myeloma and lymphoma at Swedish Cancer Institute, spoke about current treatment options and the future of care, and took questions from both the in-person and online audiences.  We invite you to watch the video.



25. Immunotherapy Combinations
http://feedproxy.google.com/~r... download (video/x-mp4, 68.95Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.



26. Immunotherapy as First-Line Treatment
http://feedproxy.google.com/~r... download (video/x-mp4, 56.23Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.



27. Lung Cancer Screening - Process and Potential Benefits
http://feedproxy.google.com/~r... download (video/x-mp4, 81.86Mb)

Description:

Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.



28. Bronchoscopy and EBUS
http://feedproxy.google.com/~r... download (video/x-mp4, 79.23Mb)

Description:

Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.



29. Maintenance Therapy for Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 63.92Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.



30. Rociletinib/Osimertinib for EGFR T790M-negative NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 61.82Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.



31. Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
http://feedproxy.google.com/~r... download (video/x-mp4, 42.49Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.



32. Histology-Specific Recommendations - Large-Cell Neuroendocrine
http://feedproxy.google.com/~r... download (video/x-mp4, 29.74Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.



33. Histology-Specific Regimens - Squamous
http://feedproxy.google.com/~r... download (video/x-mp4, 49.22Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.



34. Histology-Specific Regimens - Adenocarcinoma
http://feedproxy.google.com/~r... download (video/x-mp4, 34.34Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.



35. What is the Role of Bevacizumab in Stage IV NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 45.83Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.



36. Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment
http://feedproxy.google.com/~r... download (video/x-mp4, 53.94Mb)

Description:

Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.



37. Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 16.56Mb)

Description:

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.



38. CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
http://feedproxy.google.com/~r... download (video/x-mp4, 18.57Mb)

Description:

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.



39. Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 14.74Mb)

Description:

Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.



40. Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
http://feedproxy.google.com/~r... download (video/x-mp4, 6.76Mb)

Description:

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.



41. ROS-1 Rearrangements: What Are They?
http://feedproxy.google.com/~r... download (video/x-mp4, 14.11Mb)

Description:

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.



42. ALK Rearrangements: What Are They, and Who Has Them?
http://feedproxy.google.com/~r... download (video/x-mp4, 13.21Mb)

Description:

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.



43. Multiplex Testing for Rare Mutations: What Are the Potential Benefits?
http://feedproxy.google.com/~r... download (video/x-mp4, 21.03Mb)

Description:

Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.



44. The Role of Targeted Therapy Post-Resection
http://feedproxy.google.com/~r... download (video/x-mp4, 45.04Mb)

Description:

Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.



45. What Is a Standard Adjuvant Chemotherapy Regimen?
http://feedproxy.google.com/~r... download (video/x-mp4, 43.91Mb)

Description:

Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.



46. Why Give Adjuvant Chemotherapy, and to Which Patients?
http://feedproxy.google.com/~r... download (video/x-mp4, 23.17Mb)

Description:

Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.



47. Zoledronate or Denosumab for Lung Cancer with Bone Metastases
http://feedproxy.google.com/~r... download (video/x-mp4, 23.35Mb)

Description:

Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.



48. How Rate of Progression Can Affect Treatment Decisions
http://feedproxy.google.com/~r... download (video/x-mp4, 22.99Mb)

Description:



49. Platinum-Based Doublets As the Cornerstone of First Line Treatment
http://feedproxy.google.com/~r... download (video/x-mp4, 25.12Mb)

Description:

Dr. Benjamin Levy, Mount Sinai Health Systems, discusses platinum-based chemotherapy as the standard of care for advanced NSCLC patients without targetable genetic mutations.



50. What are the Goals of Treating Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 20.77Mb)

Description:

Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve those goals.



51. Video-Assisted Thorascopic Surgery vs. Open Thoracotomy
http://feedproxy.google.com/~r... download (video/x-mp4, 37.95Mb)

Description:

Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the newer approach.



52. What Is the Significance of Mediastinal Node Sterilization After Neoadjuvant Therapy?
http://feedproxy.google.com/~r... download (video/x-mp4, 19.70Mb)

Description:

Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.



53. What Is a Sleeve Resection?
http://feedproxy.google.com/~r... download (video/x-mp4, 17.83Mb)

Description:

Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large tumors retain lung function.



54. What Is a Mediastinoscopy?
http://feedproxy.google.com/~r... download (video/x-mp4, 20.00Mb)

Description:

Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.



55. How Do Thoracic Surgeons Assess Fitness for Surgery?
http://feedproxy.google.com/~r... download (video/x-mp4, 23.22Mb)

Description:



56. The Surgical Decision: Assessing and Discussing the Patient's Options
http://feedproxy.google.com/~r... download (video/x-mp4, 15.69Mb)

Description:

Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.



57. Is There a Role for PCI in Locally Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 39.18Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.



58. Can Immunotherapy Play a Role in Locally Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 74.73Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.



59. Appropriate Chemo Regimens with Radiation for Locally Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 32.36Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.



60. Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 43.33Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC.



61. Is There a Role for Induction or Consolidation Chemotherapy Before/After Chemo/Radiation?
http://feedproxy.google.com/~r... download (video/x-mp4, 21.73Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.



62. Chemoradiation as a Standard of Care for Unresectable NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 67.86Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III NSCLC.



63. What is Stage III Unresectable NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 23.06Mb)

Description:

Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.



64. Trends in Lung Cancer Demographics and Changes in Histology
http://feedproxy.google.com/~r... download (video/x-mp4, 10.91Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, details the trends in lung cancer demographics and changes in histology by race and gender.



65. Lung Cancer Risk Factors
http://feedproxy.google.com/~r... download (video/x-mp4, 17.04Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses smoking, asbestos, radon and other risk factors for lung cancer.



66. Lung Cancer Demographics/Epidemiology
http://feedproxy.google.com/~r... download (video/x-mp4, 7.73Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.



67. Are There Significant Genetic Risks for Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 20.59Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.



68. Local Therapy for Limited Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 21.34Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.



69. Elderly Patients: Selecting Appropriate Systemic Treatment Agents
http://feedproxy.google.com/~r... download (video/x-mp4, 26.52Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.



70. Elderly Patients: Single Agent vs. Doublet Chemotherapy
http://feedproxy.google.com/~r... download (video/x-mp4, 30.04Mb)

Description:

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.



71. The Basics of a Lung Cancer Workup
http://feedproxy.google.com/~r... download (video/x-mp4, 40.94Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.



72. What Are Pulmonary Function Tests, and How Are They Used?
http://feedproxy.google.com/~r... download (video/x-mp4, 26.69Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.



73. PET Scan Imaging: What Does It Tell Us?
http://feedproxy.google.com/~r... download (video/x-mp4, 17.16Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.



74. How a Diagnosis of Lung Cancer is Made: The Biopsy
http://feedproxy.google.com/~r... download (video/x-mp4, 13.92Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.



75. Potential Advantages, Disadvantages and Limitations of Lung Cancer Screening
http://feedproxy.google.com/~r... download (video/x-mp4, 23.99Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.



76. Detecting Lung Cancer: Presenting Symptoms
http://feedproxy.google.com/~r... download (video/x-mp4, 8.43Mb)

Description:

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.



77. Predictive Testing for Chemotherapy Responsiveness
http://feedproxy.google.com/~r... download (video/x-mp4, 37.26Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.



78. HER2 Mutation Positive NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 27.39Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.



79. ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib
http://feedproxy.google.com/~r... download (video/x-mp4, 35.14Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.



80. Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 42.77Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.



81. Third Generation EGFR TKIs for Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 29.26Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.



82. Targeted Therapies in a Post-Operative/Adjuvant Setting
http://feedproxy.google.com/~r... download (video/x-mp4, 38.97Mb)

Description:

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.



83. Induction Chemotherapy Followed by Chemo/Radiation for Stage III NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 29.35Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.



84. Management of Locally Advanced NSCLC in the Elderly and Frail
http://feedproxy.google.com/~r... download (video/x-mp4, 29.78Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.



85. Defining Resectability in Stage IIIA Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 31.28Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.



86. Neoadjuvant Chemotherapy vs. Chemo/Radiation for Stage IIIA NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 24.60Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.



87. Overall Management for Stage IIIA Disease
http://feedproxy.google.com/~r... download (video/x-mp4, 19.20Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.



88. Managing Three Compartments in Stage III Disease (Local, Distant, CNS)
http://feedproxy.google.com/~r... download (video/x-mp4, 19.59Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.



89. Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 14.73Mb)

Description:

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.



90. What is V20 and Why Do Radiation Dose & Field Size Matter?
http://feedproxy.google.com/~r... download (video/x-mp4, 32.42Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.



91. High vs. Standard Dose Chest Radiation in Stage III Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 18.75Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.



92. SBRT for Oligometastatic Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 17.42Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.



93. SBRT for Medically Inoperable Stage I Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 11.83Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.



94. What is Stereotactic Radiosurgery/Radiation Therapy to the Brain or Body?
http://feedproxy.google.com/~r... download (video/x-mp4, 7.70Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.



95. What is the Role of Molecular Marker Testing in the Adjuvant or Post-Op Setting?
http://feedproxy.google.com/~r... download (video/x-mp4, 32.35Mb)

Description:

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.



96. SBRT as a Potential Alternative for Fit Patients with Early Stage Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 16.63Mb)

Description:

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation therapy as an alternative to surgery for operable early stage lung cancer.



97. Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 20.13Mb)

Description:

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.



98. Different Lung Cancer Subtypes - Histology
http://feedproxy.google.com/~r... download (video/x-mp4, 19.56Mb)

Description:

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.



99. Immunotherapy for Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 28.22Mb)

Description:

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).



100. Second Line Chemotherapy Options for SCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 29.32Mb)

Description:

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).



101. New Approaches to Immunotherapy
http://feedproxy.google.com/~r... download (video/x-mp4, 96.01Mb)

Description:

Dr. Craig L. Slingluff, University of Virginia, discusses novel approaches to immunotherapy, including adoptive T-cell therapy, personalized cancer vaccines and personalized selection of immune therapies.



102. Novel Immunotherapies and Combinations
http://feedproxy.google.com/~r... download (video/x-mp4, 122.43Mb)

Description:

Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.



103. Immunotherapy Biomarkers and Patient Selection
http://feedproxy.google.com/~r... download (video/x-mp4, 109.36Mb)

Description:

Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.



104. Blood-Based Mutation Testing: Circulating Tumor Cells and Tumor DNA
http://feedproxy.google.com/~r... download (video/x-mp4, 19.82Mb)

Description:

Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.



105. What Is Next-Gen Sequencing?
http://feedproxy.google.com/~r... download (video/x-mp4, 29.93Mb)

Description:

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.



106. Immunotherapy for Melanoma
http://feedproxy.google.com/~r... download (video/x-mp4, 201.83Mb)

Description:

Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.



107. Immunotherapy for Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 188.25Mb)

Description:

Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.



108. Immunotherapy for Genitourinary Cancers
http://feedproxy.google.com/~r... download (video/x-mp4, 60.81Mb)

Description:

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.



109. Immunotherapy for First Line Therapy of Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 58.32Mb)

Description:

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.



110. The Patient Perspective
http://feedproxy.google.com/~r... download (video/x-mp4, 94.41Mb)

Description:

Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.



111. What is the Optimal Duration of Immunotherapy?
http://feedproxy.google.com/~r... download (video/x-mp4, 40.28Mb)

Description:



112. Managing Immunotherapy Side Effects
http://feedproxy.google.com/~r... download (video/x-mp4, 59.55Mb)

Description:

Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.



113. The Current Role of Immunotherapy in the Treatment of Patients with Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 167.89Mb)

Description:

Dr. Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, details the positive trial results for immunotherapy in a wide variety of cancers. He also describes current trials of combination regimens and the future of immunotherapy.



114. Panel Q&A Session on Patient Access and Survivorship
http://feedproxy.google.com/~r... download (video/x-mp4, 203.88Mb)

Description:

Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient support.



115. What is Immunotherapy & Its Mechanisms of Action?
http://feedproxy.google.com/~r... download (video/x-mp4, 158.85Mb)

Description:

Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.



116. Living with Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 33.24Mb)

Description:



117. Access & Assistance for ALK+, ROS1 & EGFR Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 51.64Mb)

Description:

Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.



118. Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West
http://feedproxy.google.com/~r... download (video/x-mp4, 204.34Mb)

Description:

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.



119. Treatment Options for EGFR T790M Negative Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 67.59Mb)

Description:

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.



120. Emerging Options for T790M-Positive Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 37.44Mb)

Description:



121. Individual Treatments for Individual EGFR Mutations
http://feedproxy.google.com/~r... download (video/x-mp4, 48.51Mb)

Description:

There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discuss the different activating mutations within EGFR positive tumors and how they impact treatment.



122. Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko
http://feedproxy.google.com/~r... download (video/x-mp4, 352.96Mb)

Description:

Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.



123. The Blood/Brain Barrier for ALK Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 38.77Mb)

Description:

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.



124. New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
http://feedproxy.google.com/~r... download (video/x-mp4, 98.36Mb)

Description:

Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.



125. Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn
http://feedproxy.google.com/~r... download (video/x-mp4, 266.49Mb)

Description:

Dr. West moderates a question & answer session with Drs. Leora Horn and Taofeek OwonikokGreg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.



126. What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?
http://feedproxy.google.com/~r... download (video/x-mp4, 53.91Mb)

Description:

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.



127. Repeat Biopsies and Emerging Techniologies for Plasma Sampling of Mutations Seen with Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 63.09Mb)

Description:

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biospies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.



128. Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
http://feedproxy.google.com/~r... download (video/x-mp4, 567.21Mb)

Description:

Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.



129. Time to Response to Immunotherapy and the Concept of Pseudoprogression
http://feedproxy.google.com/~r... download (video/x-mp4, 48.53Mb)

Description:

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".



130. How Important is the Impact of Smoking Cessation on Survival?
http://feedproxy.google.com/~r... download (video/x-mp4, 34.88Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.



131. Have Your Practices Changed Regarding Prophylactic Cranial Irradiation for Extensive Stage SCLC Patients?
http://feedproxy.google.com/~r... download (video/x-mp4, 30.56Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).



132. Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?
http://feedproxy.google.com/~r... download (video/x-mp4, 40.80Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.



133. What Are Your Current Practices for Consolidation Chest Radiation for Extensive SCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 24.76Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.



134. The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases
http://feedproxy.google.com/~r... download (video/x-mp4, 76.77Mb)

Description:

Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.



135. What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?
http://feedproxy.google.com/~r... download (video/x-mp4, 69.73Mb)

Description:

Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.



136. Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?
http://feedproxy.google.com/~r... download (video/x-mp4, 49.73Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.



137. Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?
http://feedproxy.google.com/~r... download (video/x-mp4, 58.83Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.



138. Can Patients Benefit from Broad vs. Focal Genetic Testing?
http://feedproxy.google.com/~r... download (video/x-mp4, 43.47Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.



139. Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
http://feedproxy.google.com/~r... download (video/x-mp4, 38.49Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.



140. Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
http://feedproxy.google.com/~r... download (video/x-mp4, 39.99Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).



141. What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?
http://feedproxy.google.com/~r... download (video/x-mp4, 39.89Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.



142. Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 48.12Mb)

Description:

As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.



143. Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
http://feedproxy.google.com/~r... download (video/x-mp4, 43.20Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.



144. What Are You Grateful For?
http://feedproxy.google.com/~r... download (video/x-mp4, 24.25Mb)

Description:

“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.



145. The Lung Cancer Master Protocol/SWOG 1400 as a Clinical Trial for a New Era of Molecular Oncology
http://feedproxy.google.com/~r... download (video/x-mp4, 48.26Mb)

Description:

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.



146. Clinical Trial Spotlight: Targeting Brain Mets in EGFR Lung Cancer Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 17.55Mb)

Description:

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.



147. In Sickness and In Health
http://feedproxy.google.com/~r... download (video/x-mp4, 15.62Mb)

Description:

On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life. November is Lung Cancer Awareness Month. What are you grateful for?



148. Clinical Trial Spotlight: Can Epigenetic Priming Improve Efficacy of Immunotherapy in NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 7.67Mb)

Description:

Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.



149. Clinical Trial Spotlight: Identifying Lung Cancer Patients Who Respond to Ponatinib
http://feedproxy.google.com/~r... download (video/x-mp4, 22.01Mb)

Description:

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib



150. Postcards from Her Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 10.99Mb)

Description:

Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?



151. Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 37.95Mb)

Description:

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.



152. Clinical Trials of Immune Checkpoint Inhibitors as FIrst Line Therapy for Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 10.94Mb)

Description:

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.



153. What is the Current Role of Serum Based Biomarker Testing?
http://feedproxy.google.com/~r... download (video/x-mp4, 60.41Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of "liquid biopsies", serum-based testing for molecular marker testing in lung cancer.



154. Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
http://feedproxy.google.com/~r... download (video/x-mp4, 40.30Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.



155. Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 50.84Mb)

Description:

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.



156. Are Immune Checkpoint Inhibitors Sufficiently Tolerable to Recommend Them for Older or More Frail Patients?
http://feedproxy.google.com/~r... download (video/x-mp4, 33.67Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.



157. Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?
http://feedproxy.google.com/~r... download (video/x-mp4, 35.66Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.



158. Do Clinical Characteristics Alter Your Enthusiasm for Immune Checkpoint inhibitors?
http://feedproxy.google.com/~r... download (video/x-mp4, 35.02Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.



159. Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 65.27Mb)

Description:

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.



160. Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 59.57Mb)

Description:

Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.



161. Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?
http://feedproxy.google.com/~r... download (video/x-mp4, 37.96Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.



162. Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 57.44Mb)

Description:

Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.



163. Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor?
http://feedproxy.google.com/~r... download (video/x-mp4, 39.57Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.



164. Clinical Trial Spotlight: Determining Efficacy of Immunotherapy in Stage III Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 66.50Mb)

Description:

Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.



165. Clinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 63.27Mb)

Description:

Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival. http://bit.ly/NCIALCHEMIST



166. Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 33.78Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.



167. Here Today Thanks to Research
http://feedproxy.google.com/~r... download (video/x-mp4, 10.00Mb)

Description:

ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?



168. First Line Treatment of EGFR Mutation-Positive NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 13.87Mb)

Description:

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.



169. Promising Early Results with Immunotherapy for Mesothelioma
http://feedproxy.google.com/~r... download (video/x-mp4, 16.57Mb)

Description:

Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.



170. Grateful for Another Great Year
http://feedproxy.google.com/~r... download (video/x-mp4, 14.31Mb)

Description:

GRACE Founder and President Dr. H. Jack West gives thanks to immunotherapies that offer new hope to his patients. November is Lung Cancer Awareness Month. What are you grateful for?



171. November is Lung Cancer Awareness Month
http://feedproxy.google.com/~r... download (video/x-mp4, 17.56Mb)

Description:

Even in the world of lung cancer, there are things to be grateful for. This November, join GRACE as we celebrate them with doctors, patients and caregivers.



172. Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
http://feedproxy.google.com/~r... download (video/x-mp4, 26.00Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.



173. ECOG 1505 Study: No Benefit of Post-Operative Avastin in Early Stage Lung Cancer Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 38.29Mb)

Description:

Drs. Ben Solomon, Leora Horn, & Jack West review trial result and implications of ECOG 1505 trial that showed no benefit to addition of Avastin (bevacizumab) to adjuvant chemotherapy for early stage NSCLC.



174. Immunotherapy for Lung Cancer: General Concepts
http://feedproxy.google.com/~r... download (video/x-mp4, 65.96Mb)

Description:

Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.



175. Should EGFR TKI Therapy be Continued Beyond Progression?
http://feedproxy.google.com/~r... download (video/x-mp4, 28.72Mb)

Description:

Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.



176. The Potential Value of Repeat Biopsies in Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 23.66Mb)

Description:

MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.



177. Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 25.13Mb)

Description:

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.



178. Are There Distinctions Among Currently Available Oral EGFR Inhibitors for EGFR Mutation-Positive NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 23.83Mb)

Description:

Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.



179. Differences Among Specific EGFR Mutations
http://feedproxy.google.com/~r... download (video/x-mp4, 28.24Mb)

Description:

Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.



180. What is EGFR and the EGFR Mutation?
http://feedproxy.google.com/~r... download (video/x-mp4, 22.43Mb)

Description:

Dr. Greg Reily from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.



181. What is the Value of Testing for Molecular Markers in Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 16.47Mb)

Description:

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.



182. Radiation Management of Limited Stage SCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 16.70Mb)

Description:

Dr. Vivek Mehta, radiation oncologist, reviews the basic principles and treatment approach for limited stage small cell lung cancer, which combines chest radiation with concurrent chemotherapy.



183. Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 20.38Mb)

Description:

Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.



184. Prophylactic Cranial Irradiation for Limited Stage Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 19.60Mb)

Description:

Radiation to the brain is a component of our treatment of limited stage small cell lung cancer, even with no evidence of cancer there. Dr. Vivek Mehta, radiation oncologist, reviews why we would do such a thing.



185. Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 70.02Mb)

Description:

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.



186. What is Maintenance Therapy for Advanced NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 53.58Mb)

Description:

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.



187. Optimal Systemic Therapy for Bronchioloalveolar Carcinoma (BAC)
http://feedproxy.google.com/~r... download (video/x-mp4, 58.60Mb)

Description:

Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.



188. Reirradiation of Tumor in a Previously Radiated Field
http://feedproxy.google.com/~r... download (video/x-mp4, 39.80Mb)

Description:

Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in a previously irradiated field.



189. Cancer Growth Rate and Managing Slow-Growing Lung Cancers
http://feedproxy.google.com/~r... download (video/x-mp4, 41.54Mb)

Description:

Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for "over-treatment."



190. What is a Pancoast Tumor and How is it Best Treated?
http://feedproxy.google.com/~r... download (video/x-mp4, 57.78Mb)

Description:

Dr. Eric Vallieres, thoracic surgeon, introduces us to and provides a brief history for the special case in lung cancer of a "Pancoast Tumor", along with how its optimal treatment has evolved over several decades.



191. Basic Principles of Managing Locally Advanced NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 43.05Mb)

Description:

Dr. West reviews basic principles of treating locally advanced lung cancer, including the need to treat both local disease and possible distant disease, and the need to balance efficacy with toxicity.



192. Pre-Operative/Neoadjuvant Therapy: Rationale and Indications
http://feedproxy.google.com/~r... download (video/x-mp4, 34.67Mb)

Description:

Thoracic Surgeon Dr. Eric Vallieres reviews the principle of giving chemotherapy prior to lung cancer surgery in order to improve survival and potentially make it possible to do a smaller lung surgery.



193. Surgery Options for Smaller, Slow-Growing Lung Cancers
http://feedproxy.google.com/~r... download (video/x-mp4, 42.77Mb)

Description:

Dr. Eric Vallieres, thoracic surgeon, discusses the potential to do smaller lung surgeries on patients with a lung cancer that poses a minimal risk of recurrence.



194. Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?
http://feedproxy.google.com/~r... download (video/x-mp4, 30.81Mb)

Description:

Current clinical trials are examining the possibility of giving kidney cancer (also called renal cell carcinoma, or RCC) patients immunotherapy as their first option of care upon diagnosis.



195. Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
http://feedproxy.google.com/~r... download (video/x-mp4, 90.73Mb)

Description:

The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).



196. Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable Early Stage Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 35.38Mb)

Description:

Dr. Chris Loiselle, radiation oncologist, describes stereotactic body radiation therapy (SBRT) as a helpful and increasingly favored treatment option for sicker, "medically inoperable" patients with early stage lung cancer.



197. Special Considerations for Lung Cancer Surgery in the Elderly
http://feedproxy.google.com/~r... download (video/x-mp4, 32.03Mb)

Description:

Should older patients with lung cancer undergo surgery? What issues affect the probability of an elderly patients safely undergoing lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, provides an expert perspective.



198. Challenges of Pneumonectomy Surgery
http://feedproxy.google.com/~r... download (video/x-mp4, 21.52Mb)

Description:

Dr. Eric Vallières, thoracic surgeon, describes the phsycial challenges and risks for patients who undergo a pneumonectomy for lung cancer.



199. Types of Lung Surgery: From Wedge Resection to Pneumonectomy
http://feedproxy.google.com/~r... download (video/x-mp4, 23.42Mb)

Description:

There are multiple different types of lung cancer surgery. Dr. Eric Vallières, thoracic surgeon, reviews the different forms of lung surgery, include wedge resection, segmentectomy, lobectomy, and pneumonectomy.



200. Defining TNM Staging and Early Stage NSCLC
http://feedproxy.google.com/~r... download (video/x-mp4, 24.20Mb)

Description:

Dr. Eric Vallières, thoracic surgeon, reviews the structure and purpose of staging using the current tumor-node-metastasis (TNM) system for lung cancer.



201. Managing Malignant Pleural Effusions: Pleurodesis
http://feedproxy.google.com/~r... download (video/x-mp4, 81.58Mb)

Description:

Dr. Jed Gorden reviews the technique of pleurodesis to manage the complication of recurrent malignant pleural effusion (MPE).



202. Managing Malignant Pleural Effusions: Tunneled Pleural Catheter
http://feedproxy.google.com/~r... download (video/x-mp4, 95.92Mb)

Description:

A tunneled pleural catheter is an excellent way to manage the symptoms of a recurrent malignant pleural effusion. Dr. Jed Gorden describes how it is placed and how it works.



203. Managing Malignant Pleural Effusions: Thoracentesis
http://feedproxy.google.com/~r... download (video/x-mp4, 75.40Mb)

Description:

Dr. Jed Gorden describes the details of how a thoracentesis is performed in order to clarify the diagnosis and treat symptoms of a malignant pleural effusion (MPE).



204. Introduction to Malignant Pleural Effusions
http://feedproxy.google.com/~r... download (video/x-mp4, 36.88Mb)

Description:

Interventional pulmonologist Dr. Jed Gorden reviews malignant pleural effusions (MPEs) are a common complication of lung cancer and some other cancers.



205. What is the Role of Memantine for Neuroprotection During Whole Brain Irradiation?
http://feedproxy.google.com/~r... download (video/x-mp4, 19.50Mb)

Description:

What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems.



206. Palliative Radiation for Bone Metastases
http://feedproxy.google.com/~r... download (video/x-mp4, 24.03Mb)

Description:

Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach. 



207. Liquid Biopsies: Faster Results, Easier on Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 83.54Mb)

Description:

Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?



208. BRAF: A New Target to Treat in Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 70.57Mb)

Description:

A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.



209. Improved Survival in Malignant Pleural Mesothelioma with Avastin Added to Chemotherapy
http://feedproxy.google.com/~r... download (video/x-mp4, 76.22Mb)

Description:

A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.



210. Which Patients with Lung Cancer Should Receive Whole Brain Radiation Therapy?
http://feedproxy.google.com/~r... download (video/x-mp4, 117.62Mb)

Description:

Managing brain metastases is a big concern for lung cancer patients. The doctors discuss the drawbacks of whole brain radiotherapy and the fact that there are still unknowns regarding more targeted stereotactic radiosurgery.



211. Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?
http://feedproxy.google.com/~r... download (video/x-mp4, 49.85Mb)

Description:

A Japanese study of squamous cell carcinoma showed value in nedaplatin vs cisplatin/Taxotere (docetaxel). But with differences in how Asian versus Caucasian patients metabolize chemotherapy, can we presume this benefit would exist for everyone?



212. RET in Lung Cancer: The Next Big Target?
http://feedproxy.google.com/~r... download (video/x-mp4, 55.08Mb)

Description:

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.



213. Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
http://feedproxy.google.com/~r... download (video/x-mp4, 44.56Mb)

Description:

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.



214. Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 127.54Mb)

Description:

Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.



215. Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
http://feedproxy.google.com/~r... download (video/x-mp4, 80.99Mb)

Description:

The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).



216. Immunotherapy Combinations: Best Balance of Activity and Tolerability?
http://feedproxy.google.com/~r... download (video/x-mp4, 89.37Mb)

Description:

As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.



217. Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
http://feedproxy.google.com/~r... download (video/x-mp4, 103.64Mb)

Description:

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?



218. Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
http://feedproxy.google.com/~r... download (video/x-mp4, 179.32Mb)

Description:

The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?



219. Immunotherapy for Squamous Non-Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 129.50Mb)

Description:

Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?



220. Whole Brain Radiation for Brain Metastases
http://feedproxy.google.com/~r... download (video/x-mp4, 43.60Mb)

Description:

Radiation Oncologist Dr. Vivek Mehta reviews the concept of using whole brain radiation for multiple brain metastases, including how it is delivered and risks and benefits of this strategy.



221. Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA
http://feedproxy.google.com/~r... download (video/x-mp4, 49.39Mb)

Description:

Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies.



222. Myths and Misconceptions About Bronchioloalveolar Carcinoma (BAC)
http://feedproxy.google.com/~r... download (video/x-mp4, 78.70Mb)

Description:

Unfortunately, there is as much misinformation as good information about the unusual subtupe of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths.



223. Bronchioloalveolar Carcinoma (BAC): What is It?
http://feedproxy.google.com/~r... download (video/x-mp4, 37.23Mb)

Description:

Bronchioloalveolar carcinoma (BAC), also known as adenocarcinoma in situ, is an unusual subtype of lung cancer with its own appearance under a microscope and on imaging. Dr. Jack West introduces some of the basics of the unique features of BAC.



224. Questions & Answers with Drs. Pal, Luke and Wolchok about Immunotherapy for Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 189.64Mb)

Description:

Immunotherapy Forum Video #31: "You know the world is changing when you have to change the rules..." Following presentations on endpoints and biomarkers in cancer immunotherapy, the doctors take questions from the audience.



225. Redefining Success and Failure in Cancer Immunotherapy Trials
http://feedproxy.google.com/~r... download (video/x-mp4, 58.75Mb)

Description:

Immunotherapy Forum Video #30: Immunotherapy for cancer has rewritten the rules for what we consider a successful response to treatment. Some tumors grow before they regress. Dr. Jedd Wolchok discusses why a new measurement criteria was developed.



226. The Future of Cancer Immunotherapy: Combination Treatments
http://feedproxy.google.com/~r... download (video/x-mp4, 45.81Mb)

Description:

Immunotherapy Forum Video #29: In part 2 of 2, Dr. Jason Luke discusses treating cancer with immunotherapy and another drug, such chemotherapy or targeted therapies, as well as what we know about biomarkers that predict if an immunotherapeutic will work.



227. The Right Time for Cancer Immunotherapy: Before or After Surgery?
http://feedproxy.google.com/~r... download (video/x-mp4, 47.48Mb)

Description:

Immunotherapy Forum Video #28: Doctors are still weighing the pros and cons of giving a cancer patient immunotherapy before or after resection surgery. In part 1 of 2 videos, Dr. Jason Luke details those risks and benefits.



228. Who Benefits from Immunotherapy?
http://feedproxy.google.com/~r... download (video/x-mp4, 61.18Mb)

Description:

Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.



229. Lung Cancer Immunotherapy Q&A
http://feedproxy.google.com/~r... download (video/x-mp4, 190.76Mb)

Description:

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.



230. Benjamin Levy, MD, Hails 2015 as the Year of Lung Cancer Clinical Trials
http://feedproxy.google.com/~r... download (video/x-mp4, 20.31Mb)

Description:

Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.



231. Immunotherapy for Lung Cancer: Currently Enrolling Clinical Trials of Combination Therapies
http://feedproxy.google.com/~r... download (video/x-mp4, 39.74Mb)

Description:

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).



232. Currently Enrolling Clinical Trials of Single Agent Immunotherapies for Patients with Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 41.11Mb)

Description:

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).



233. What We Know About Immunotherapy Treatments for Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 59.76Mb)

Description:

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."



234. Kidney Cancer Immunotherapy Q&A
http://feedproxy.google.com/~r... download (video/x-mp4, 140.22Mb)

Description:

Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.



235. Kidney Cancer Immunotherapy: Reasons for Cautious Optimism
http://feedproxy.google.com/~r... download (video/x-mp4, 76.60Mb)

Description:

Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 



236. Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials
http://feedproxy.google.com/~r... download (video/x-mp4, 44.67Mb)

Description:

Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 



237. Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials
http://feedproxy.google.com/~r... download (video/x-mp4, 65.09Mb)

Description:

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.



238. Lung Squamous Cancer 201: New Promise in Treatments
http://feedproxy.google.com/~r... download (video/x-mp4, 64.86Mb)

Description:

In Part 2 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains the value of patients receiving molecular profiling of their tumor, the vital role of clinical trials, and the promise of immunotherapy for treating this type of lung cancer.



239. Lung Squamous Cancer 201: Understanding Your Disease
http://feedproxy.google.com/~r... download (video/x-mp4, 90.80Mb)

Description:

In Part 1 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains what doctors look for and ask about when diagnosing lung cancer, and how you can be sure you received the correct diagnosis.



240. Questions & Answers with Drs. Topalian and Wolchok about Immunotherapy for Melanoma
http://feedproxy.google.com/~r... download (video/x-mp4, 153.47Mb)

Description:

Immunotherapy Forum Video #18: Drs. Topalian and Wolchok sat for a moderated Q&A with Dr. Louise Perkins from the Melanoma Research Alliance following their presentations on immunotherapy for melanoma.



241. Melanoma Immunotherapy, Pt. 2: The End of the Beginning
http://feedproxy.google.com/~r... download (video/x-mp4, 44.52Mb)

Description:

Immunotherapy Forum Video #17: In Part 2 of 2 videos on this topic, Dr. Jedd Wolchok discusses side effects related to immunotherapy, combination therapies, and information about new immunotherapies currently being studied for treating melanoma.



242. Melanoma Immunotherapy, Pt. 1: The End of the Beginning
http://feedproxy.google.com/~r... download (video/x-mp4, 39.52Mb)

Description:

Immunotherapy Forum Video #16: In Part 1 of 2 videos on this topic, Dr. Jedd Wolchok provides a history of one of the first immunotherapy drugs, Yervoy (ipilumumab), and the evidence that led to its approval.



243. Immunotherapy for Melanoma, Pt. 2: Immune Checkpoints & the Drugs That Block Them
http://feedproxy.google.com/~r... download (video/x-mp4, 53.31Mb)

Description:

Immunotherapy Forum Video #15: In Part 2 of 2 videos on this topic, Dr. Suzanne Topalian discusses the immunotherapy drugs that are currently approved for the treatment of melanoma as well as future treatments on the horizon.



244. Immunotherapy for Melanoma, Pt. 1: An Overview
http://feedproxy.google.com/~r... download (video/x-mp4, 55.26Mb)

Description:

Immunotherapy Forum Video #14: In Part 1 of 2 videos on this topic, Dr. Suzanne Topalian provides a background on melanoma in the United States and how immunotherapy treatment for it has progessed over the past three decades.



245. Questions & Answers with Drs. Davies and Atkins, and patient Rusty Cline
http://feedproxy.google.com/~r... download (video/x-mp4, 190.92Mb)

Description:

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.



246. Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 2
http://feedproxy.google.com/~r... download (video/x-mp4, 61.78Mb)

Description:

Immunotherapy Forum Video #12: In Part 2 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.



247. Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 40.24Mb)

Description:

Immunotherapy Forum Video #11: In Part 1 of 2 videos on this topic, Dr. Michael Atkins explains why immunotherapy appears to be more effective in such cancers as melanoma, lymphomas, and kidney, lung, bladder, and head and neck cancers.



248. The Patient Perspective
http://feedproxy.google.com/~r... download (video/x-mp4, 78.60Mb)

Description:

Immunotherapy Forum Video #10: "For all of the scholarly individuals here to give you the science, I'm here to give you the proof," is how stage IV melanoma patient Rusty Cline kicks off the story of his remarkable response to immunotherapy. 



249. Managing Immunotherapy Side Effects - Part 2
http://feedproxy.google.com/~r... download (video/x-mp4, 38.74Mb)

Description:

Immunotherapy Forum Video #9: In Part 2 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.



250. Managing Immunotherapy Side Effects - Part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 50.69Mb)

Description:

Immunotherapy Forum Video #8: In Part 1 of 2 videos on this topic, oncology nurse Dr. Marianne Davies discusses the side effects that cancer patients who undergo immunotherapy treatment may experience and how to minimize them.



251. Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West
http://feedproxy.google.com/~r... download (video/x-mp4, 162.00Mb)

Description:

Immunotherapy Forum Video #7: Drs. Pardoll, Hellman, and Luke sat for a moderated Q&A with Dr. Jack West.



252. How Immunotherapy is Administered - Part 2
http://feedproxy.google.com/~r... download (video/x-mp4, 36.76Mb)

Description:

Immunotherapy Forum Video #6: In Part 2 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.



253. How Immunotherapy is Administered - Part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 43.83Mb)

Description:

Immunotherapy Forum Video #5: In Part 1 of 2 videos on this topic, Dr. Jason Luke from the University of Chicago talks about the types of immunotherapy currently in use for melanoma, kidney cancer, and lung cancer and how they are given to patients.



254. Dr. Geoffrey Oxnard: My Top Highlight in Lung Cancer from 2014 - Liquid Biopsies
http://feedproxy.google.com/~r... download (video/x-mp4, 36.71Mb)

Description:

There were many advances in lung cancer targeted treatments in 2014. The one that most excites Dr. Geoffrey Oxnard from Dana-Farber Cancer Institute is the use of liquid biopsies.



255. History of Immunotherapy in Cancer - Part 2
http://feedproxy.google.com/~r... download (video/x-mp4, 44.08Mb)

Description:

Immunotherapy Forum Video #4: In Part 2 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.



256. History of Immunotherapy in Cancer - Part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 41.53Mb)

Description:

Immunotherapy Forum Video #3: In Part 1 of 2 videos on this topic, Dr. Matthew Hellmann from the Memorial Sloan Kettering Cancer Center discusses the century-long history of attempting to treat cancer with immunotherapy.



257. What is Immunotherapy and its Mechanisms of Action? Part 2
http://feedproxy.google.com/~r... download (video/x-mp4, 55.32Mb)

Description:

Immunotherapy Forum Video #2: In Part 2 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.



258. What is Immunotherapy and its Mechanisms of Action? Part 1
http://feedproxy.google.com/~r... download (video/x-mp4, 74.58Mb)

Description:

Immunotherapy Forum Video #1: In Part 1 of 2 videos on this topic, Dr. Drew Pardoll from the Kimmel Cancer Center at Johns Hopkins explains what immunotherapy is and how it helps cancer patients live longer - many for five years or more.



259. Donating to GRACE is Equivalent to a Dose of Hope
http://feedproxy.google.com/~r... download (video/x-mp4, 19.28Mb)

Description:

Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, gives thanks to GRACE this week and urges others to do the same.



260. It's Possible to Live WITH Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 54.10Mb)

Description:

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Linnea Duff, a 10-year stage IV ALK+ lung cancer patient, shares her journey from stunned patient to empowered patient.



261. Novel EGFR Inhibitors in the Setting of Acquired Resistance
http://feedproxy.google.com/~r... download (video/x-mp4, 398.75Mb)

Description:

Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.



262. He Said, She Said - The Doctor/Patient Relationship
http://feedproxy.google.com/~r... download (video/x-mp4, 43.21Mb)

Description:

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jared Weiss, GRACE Vice President, and his patient Tomma Hargraves, discuss how they became a team.



263. Questions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack West
http://feedproxy.google.com/~r... download (video/x-mp4, 374.07Mb)

Description:

Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.



264. Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
http://feedproxy.google.com/~r... download (video/x-mp4, 186.57Mb)

Description:

Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.



265. The best thing you can do as a cancer patient...
http://feedproxy.google.com/~r... download (video/x-mp4, 59.13Mb)

Description:

November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jack West, GRACE founder and president, explains the steps that patients can do become empowered.



266. The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
http://feedproxy.google.com/~r... download (video/x-mp4, 375.15Mb)

Description:

Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.



267. Leveraging Patient Engagement & the Role of Advocacy
http://feedproxy.google.com/~r... download (video/x-mp4, 305.01Mb)

Description:

Acquired Resistance Forum Video #11: Bonnie J. Addario, founder of the Addario Lung Cancer Foundation described how the lung cancer community can work together to support each other and affect change for all patients.



268. Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe
http://feedproxy.google.com/~r... download (video/x-mp4, 207.69Mb)

Description:

Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.



269. Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
http://feedproxy.google.com/~r... download (video/x-mp4, 442.63Mb)

Description:

Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.



270. Mechanisms of ALK Resistance & Implications for Treatment
http://feedproxy.google.com/~r... download (video/x-mp4, 350.93Mb)

Description:

Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.



271. Questions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. West
http://feedproxy.google.com/~r... download (video/x-mp4, 252.01Mb)

Description:

Acquired Resistance Forum Video #7: Speakers from videos #5 and #6 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.



272. Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations
http://feedproxy.google.com/~r... download (video/x-mp4, 371.27Mb)

Description:

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.



273. Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
http://feedproxy.google.com/~r... download (video/x-mp4, 372.28Mb)

Description:

Acquired Resistance Forum Video #5: Dr. Gideon Blumenthal of the US Food and Drug Administration (FDA) discussed the FDA process for approving targeted therapies.



274. Questions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. West
http://feedproxy.google.com/~r... download (video/x-mp4, 435.25Mb)

Description:

Acquired Resistance Forum Video #4: The first three speakers at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West. 



275. Repeat Biopsies & the Potential Value of Biologically-Informed Acquired Resistance Therapy
http://feedproxy.google.com/~r... download (video/x-mp4, 363.42Mb)

Description:

Acquired Resistance Forum Video #3: Dr. Lecia Sequist of Massachusetts General Hospital detailed why doctors started doing repeat biopsies for patients receiving targeted therapies and how they help patients and doctors determine next steps in treatment.



276. Life After 1st Line Targeted Therapy: What Next?
http://feedproxy.google.com/~r... download (video/x-mp4, 384.08Mb)

Description:

Acquired Resistance Forum Video #2: Dr. Jared Weiss of the University of North Carolina addressed the Acquired Resistance in Lung Cancer Patient Forum with information on what patients' options are when their ALK, ROS1 or EGFR lung cancer progresses. September 2014



277. What is Acquired Resistance and How Does it Occur?
http://feedproxy.google.com/~r... download (video/x-mp4, 302.37Mb)

Description:

Acquired Resistance Forum Video #1: Dr. Gregory J. Riely of Memoral Sloan Kettering Cancer Center opened the Acquired Resistance in Lung Cancer Patient Forum with a basic introduction of how ALK, ROS1 and EGFR lung cancers become resistant to treatment. September 2014



278. Doctors Discuss: Immunotherapy in Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 376.76Mb)

Description:

Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014



279. Understanding Acquired Resistance in ALK+ Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 42.11Mb)

Description:

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014



280. Treating Brain Mets in ALK+ Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 67.08Mb)

Description:

For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014



281. Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?
http://feedproxy.google.com/~r... download (video/x-mp4, 15.51Mb)

Description:

For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014



282. Sym-004 Offers Hope for EGFR Wild Type Lung Cancer Patients
http://feedproxy.google.com/~r... download (video/x-mp4, 37.70Mb)

Description:

Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014



283. It's Time to Get Over the Lung Cancer Stigma
http://feedproxy.google.com/~r... download (video/x-mp4, 52.69Mb)

Description:

The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.



284. Molecular Testing in Early Stage Non-Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 57.57Mb)

Description:

Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014



285. Targeted Therapies for Stage III Non-Small Cell Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 37.29Mb)

Description:

Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.



286. Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?
http://feedproxy.google.com/~r... download (video/x-mp4, 57.33Mb)

Description:

A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.



287. I'm Very Optimistic. For the First Time.
http://feedproxy.google.com/~r... download (video/x-mp4, 23.03Mb)

Description:

Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014



288. Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?
http://feedproxy.google.com/~r... download (video/x-mp4, 65.00Mb)

Description:

Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014



289. Will HER2 Inhibitor Drugs Help Lung Cancer Patients?
http://feedproxy.google.com/~r... download (video/x-mp4, 95.97Mb)

Description:

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.



290. Treating Leptomeningeal Carcinomatosis in Lung Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 32.69Mb)

Description:

Leptomeningeal carcinomatosis is cancer that has spread to the coating of the brain and spinal cord. In the past, prognosis has been bad. But now doctors are learning of effective treatments to deal with this issue.



291. What is the Northwestern Medical Developmental Therapeutics Institute?
http://feedproxy.google.com/~r... download (video/x-mp4, 35.27Mb)

Description:

The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.



292. How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
http://feedproxy.google.com/~r... download (video/x-mp4, 95.96Mb)

Description:

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.



293. Immunotherapy Treatments for Kidney Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 53.07Mb)

Description:

Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.



294. Evaluating Biomarkers in Kidney Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 51.20Mb)

Description:

Biomarkers can give clues to many predictive and prognostic issues, like how a patient may respond to a drug or if a patient's cancer is likely to recur. Dr. Daniel Heng discusses what researchers are learning.



295. Will Combining Immunotherapies Better Fight Kidney Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 78.15Mb)

Description:

Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.



296. Cabozantinib for Late Stage Kidney Cancer
http://feedproxy.google.com/~r... download (video/x-mp4, 39.57Mb)

Description:

Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer.



297. Immunotherapy: What Has a Year’s Experience Taught Us Since ASCO 2013?
http://feedproxy.google.com/~r... download (video/x-mp4, 59.71Mb)

Description:

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.



298. The Best Thing You Can Do As a Kidney Cancer Patient
http://feedproxy.google.com/~r... download (video/x-mp4, 23.19Mb)

Description:

Dr. Daniel Heng has advice to kidney cancer patients who want the best treatment for their disease. To find a clinical trial that is right for you, visit clinicaltrials.gov and enter "kidney cancer" in the search box.



299. RADIANT and SELECT: Is Adjuvant Erlotinib Effective in Early-Stage Lung Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 100.48Mb)

Description:

Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Eroltinib for early-stage lung cancer.



300. Are There PD1 Biomarkers in Kidney Cancer?
http://feedproxy.google.com/~r... download (video/x-mp4, 35.00Mb)

Description:

Predictive biomarkers can indicate if a patient will respond to a particular therapy. Dr. Lauren Harshman discusses if researchers know of any biomarkers for kidney cancer patients taking PD1 inhibitor drugs.